SELUTION SLR Sirolimus Drug Eluting Balloon for Endovascular Applications Receives CE Approval: Award Supported by 2 Year Results from the SELUTION SLR First-in-Human Study Involving 50 Patients

Proximie Raises $38m Series B Funding To Accelerate Its Expansion in U.S. and European Markets

F-Prime Capital led financing, joined by Questa Capital, Eight Roads, and Maverick Ventures

RhoVac Reports to Mount Sinai Hospital in New York Join Phase IIb Study in Prostate Cancer

The participation of Mount Sinai was directly caused by the FDA approval of RhoVac's Fast Track Designation.

February 3, 2020

SELUTION SLR Sirolimus Drug Eluting Balloon (DEB), for the treatment of peripheral arterial disease has received the CE Mark. This approval applies to sizes from 2.0 x 20mm to 7.0 x 150mm.

This award was supported by two-year results from the SELUTION SLR First-in-Human study, involving 50 patients enrolled across four German centres. SELUTION SLR is the first and only sirolimus drug eluting balloon to have 6 months’ clinical follow-up demonstrating a 2.3% Target Lesion Revascularization (TLR) and a 0.19 Late Lumen Loss (LLL). Two-year clinical results confirmed no deaths or amputations. Patients demonstrated clinical improvement as measured by Rutherford Classification, ABI and walking distance at 6 months and one year, which was maintained out to two years. This evidence demonstrates that a sustained limus release drug eluting balloon is both safe and effective for the treatment of femoropopliteal lesions over a prolonged period.

The study involved 50 patients enrolled across four German centres and achieved excellent freedom from TLR through to two years in 87.5% of subjects, with no primary TLR event observed after Month 11. These figures are low compared to reported historical First-in-Human studies. There were no incidences of death or the need for minor and/or major amputations over this period. These Patients demonstrated clinical improvement as measured by Rutherford Classification, ABI and walking distance at six months and one year, which was maintained out to two years.

“We are very excited to have been awarded our first CE Mark, which is testament to the documented efficacy and safety of our novel sustained limus release eluting balloon”, said MedAlliance Chairman and CEO Jeffrey B. Jump. “We now anticipate that patients in all markets where the CE Mark is recognized will be able to benefit from this breakthrough in drug eluting technology.”

MedAlliance has recently announced completion of its Below The Knee (BTK) First-in-Human study in Singapore. Studies in Arterial Venus Fistula (AVF) and Pedal Arch are to start enrolling soon. A 500 patient post marketing clinical study will follow shortly.

SELUTION SLR Sirolimus Drug Eluting Balloon technology involves unique Micro-Reservoirs made from biodegradable polymer intermixed with the anti-restenotic drug sirolimus. These micro-reservoirs provide controlled and sustained release of the drug. Extended release of sirolimus from stents has been demonstrated highly efficacious in both coronary and peripheral vasculatures. MedAlliance’s proprietary CAT™ (Cell Adherent Technology) enables the micro-reservoirs to be coated onto balloons and adhered to the vessel lumen when delivered via an angioplasty balloon.

 

spot_img

DON'T MISS

Related Articles